BioCryst Pharmaceuticals, Inc. (BCRX) Stock: Is This Biotech Stock Worth Your Consideration?

0

BioCryst Pharmaceuticals, Inc. (BCRX) is making a move down in the market today. The stock, focused in the biotechnology space, is currently priced at $2.03 after heading down -6.02% so far in today’s session. In terms of biotechnology companies, there are a number of aspects that have the potential to lead to movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines associated with BCRX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-05-19 06:53AM The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst’s Edema Drug In Japan, Myriad’s Q1 Disappointment
01:05AM BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks
Nov-04-19 07:00AM BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov-01-19 10:03AM Baker Brothers Make $1.4 Billion in Two Weeks on Biotech
07:00AM BioCryst Begins Phase 1 Trial With BCX9250, an Oral ALK-2 Inhibitor, for Treatment of Fibrodysplasia Ossificans Progressiva

Nonetheless, when making a decision with regard to investing, investors should take a look at far more than just news, this is especially the case in the highly speculative biotechnology sector. Here’s what’s happening in regard to BioCryst Pharmaceuticals, Inc..

What We’ve Seen From BCRX

Although a move down on a single session, like the move that we’re seeing from BioCryst Pharmaceuticals, Inc. may cause fear in some investors, a single session decline by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It’s always important to take a look at trends experienced by the stock for a period longer than a single trading day. As it relates to BCRX, here are the trends that investors have experienced:

  • Past Seven Days – Over the last five trading sessions, BCRX has seen a change in value in the amount of -11.74%.
  • Monthly – The monthly returns from BioCryst Pharmaceuticals, Inc. has been -22.52%.
  • Past Quarter – In the past quarter, the company has generated a ROI that comes to -26.98%
  • Past Six Months – Throughout the past 6 months, investors have seen a performance that equates to -74.01% from the company.
  • Year To Date – Since the the first trading session of this year BCRX has produced a return of -74.85%.
  • Annually – Finally, in the last full year, we have seen movement of -74.59% out of BCRX. Over this period of time, the stock has traded at a high of -79.60% and a low price of 4.10%.

Notable Ratios

Digging into various key ratios associated with a stock generally gives prospective traders a look of how dangerous and/or rewarding a pick may be. Below are a few of the important ratios to look at when digging into BCRX.

Short Ratio – The short ratio is a measure of short interest. As the short ratio heads up, it means that more investors are expecting that the value of the stock is headed for declines. Across the sector, biotech stocks can come with a higher short ratio. However, we also see a lot of short squeezes in the industry. Nonetheless, as it relates to BioCryst Pharmaceuticals, Inc., the stock’s short ratio clocks in at 9.52.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Basically, they measure If a company is able to pay for its debts as they mature based on current assets or quick assets. In the biotechnology industry, many companies rely on continued support from investors, the quick and current ratios can be bad. Nonetheless, some gems in the biotech industry do have positive quick and current ratios. As far as BCRX, the quick and current ratios total up to 1.40 and 1.40 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the share price. as it relates to BioCryst Pharmaceuticals, Inc., the book to share value ratio equates to -0.08.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology space, this is an important ratio to look into. When it comes to BCRX, the cash to share value comes to 0.84.

How Analysts Feel About BioCryst Pharmaceuticals, Inc.

Although it’s not a good idea to blindly follow the thoughts of analysts, it is a good idea to use their opinions in order to validate your own before making an investment decision in the biotech industry. Here are the recent moves that we’ve seen from analysts when it comes to BCRX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-24-19 Downgrade RBC Capital Mkts Outperform → Sector Perform $16 → $4.50
Nov-16-18 Resumed Piper Jaffray Overweight $15
Aug-08-18 Resumed JP Morgan Overweight $9
Jul-17-18 Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18 Initiated Seaport Global Securities Neutral

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in BCRX, here’s what we’re seeing:

  • Institutions – At the moment, institutions own 95.10% of the company. Nonetheless, it’s important to consider that the ownership held by institutions has seen a move of 2.66% over the past 3 months.
  • Investors On The Inside – As far as insiders go, those close to the company currently own 0.20% of BioCryst Pharmaceuticals, Inc.. Their ownership of the company has changed by -19.88% in the past quarter.

Looking At Share Counts

Traders tend to have an interest in the counts of shares both available and outstanding. With respect to BioCryst Pharmaceuticals, Inc., there are currently 110.34M with a float of 109.30M. These numbers mean that of the total of 110.34M shares of BCRX in existence today, 109.30M are available to trade hands in the public realm.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to BCRX, the short percent of the float is 12.75%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.03. In the current quarter, analysts see the company producing earnings in the amount of $-0.32. Over the last 5 years, BCRX has generated revenue in the amount of $3.60% with earnings coming in at -12.50%. On a quarter over quarter basis, earnings have seen movement of -82.60% and revenue has seen movement of -88.80%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was created by a human and human beings actually play a crucial part in my ability to learn. Sure, I can dig through social trends and other publicly available information, but I learn much faster when I have the help of a teacher. If you would to help me learn something, I’d love to learn! Is there other data that captures your interest? Should I say something differently? Is there another way to look at data? If so, leave a comment below and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here